CASI Pharmaceuticals, Inc. (CASI): Price and Financial Metrics


CASI Pharmaceuticals, Inc. (CASI)

Today's Latest Price: $1.90 USD

0.13 (-6.40%)

Updated Oct 29 1:41pm

Add CASI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

CASI Stock Summary

  • For CASI, its debt to operating expenses ratio is greater than that reported by just 0.41% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, CASI Pharmaceuticals Inc's debt growth rate surpasses merely 0% of about US stocks.
  • Revenue growth over the past 12 months for CASI Pharmaceuticals Inc comes in at 147.11%, a number that bests 96.01% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CASI, based on their financial statements, market capitalization, and price volatility, are VRAY, CYBR, VERI, RCON, and NEWR.
  • CASI's SEC filings can be seen here. And to visit CASI Pharmaceuticals Inc's official web site, go to www.casipharmaceuticals.com.

CASI Stock Price Chart Interactive Chart >

Price chart for CASI

CASI Price/Volume Stats

Current price $1.90 52-week high $3.57
Prev. close $2.03 52-week low $1.15
Day low $1.88 Volume 298,878
Day high $2.03 Avg. volume 324,321
50-day MA $1.68 Dividend yield N/A
200-day MA $2.05 Market Cap 235.49M

CASI Pharmaceuticals, Inc. (CASI) Company Bio


CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. The company was founded in 1991 and is based in Rockville, Maryland.


CASI Latest News Stream


Event/Time News Detail
Loading, please wait...

CASI Latest Social Stream


Loading social stream, please wait...

View Full CASI Social Stream

Latest CASI News From Around the Web

Below are the latest news stories about CASI Pharmaceuticals Inc that investors may wish to consider to help them evaluate CASI as an investment opportunity.

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Top Emerging Players are Ablyn, Aryogen Farmad, CASI Pharmaceuticals Inc., CELGENE CORPORATION, Celltrion Inc., GlaxoSmithKline plc

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market By Drug (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Pipeline Analysis), Application (Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis, Crohn’s Disease, Plaque Psoriasis, Ulcerative Colitis, Hidradenitis Suppurativa, Juvenile Arthritis, Uveitis, Others), Product (Humira, Enbrel, Remicade,

OpenPR | September 30, 2020

CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd

ROCKVILLE, Md. and BEIJING, Sept. 29, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced a restructuring of its partnership with…

PR Newswire | September 29, 2020

CASI Pharmaceuticals EPS misses by $0.01, misses on revenue

CASI Pharmaceuticals (CASI): Q2 GAAP EPS of -$0.09 misses by $0.01.Revenue of $2.67M misses by $1.08M.Shares +2.12% PM.Press Release...

Seeking Alpha | August 10, 2020

CASI Pharma +11.9% as CEO buys nearly $7.9M worth

CASI Pharmaceuticals (CASI) is up 11.9% after hours following news that its Chairman/CEO, Wei-Wu He, bought nearly $7.9M worth of the company's stock. He directly purchased 2,952,426 shares on Wednesday at an average price of $1.90, bringing direct beneficial ownership to 4,836,523 shares, according to an SEC filing. He also...

Seeking Alpha | July 24, 2020

CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock

ROCKVILLE, Md. and BEIJING, July 22, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public…

PR Newswire | July 22, 2020

Read More 'CASI' Stories Here

CASI Price Returns

1-mo 22.58%
3-mo -1.55%
6-mo 13.77%
1-year -42.77%
3-year -8.21%
5-year 49.61%
YTD -38.51%
2019 -23.13%
2018 23.69%
2017 182.61%
2016 19.79%
2015 -27.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9353 seconds.